Sinopharm : ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF CNMDC FOR THE YEAR ENDED 31 DECEMBER 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF CNMDC FOR THE YEAR ENDED 31 DECEMBER 2020

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement dated 18 March 2021 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the audited financial statements for the year ended 31 December 2020 of China National Medical Device Co., Ltd. (中國醫療器械有限公司)("CNMDC"), a subsidiary of the Company, issued by CNMDC on the websites of China Money and Shanghai Clearing House.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of CNMDC for the year ended 31 December 2020 as set out in this Announcement.

PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS

Unit: Yuan Currency: RMB

The year of 2020	The year of 2019	Changes of this year compared with last year
Revenue	58,358,154,272.02	45,506,575,627.07	28.24%
Operating profit	2,719,635,894.36	1,567,518,106.63	73.50%
Total comprehensive income attributable to owners of the parent company 1,300,766,256.52 589,871,918.73 120.52%Net cash flow arising from operating activities 2,004,368,189.11 1,614,606,365.02 24.14% At 31 December 2020 At 31 December 2019 Changes of 2020 year-end over 2019 year-end 38,228,498,838.96 5,347,282,079.29 28,291,560,694.33 4,183,256,826.47 35.12% 27.83%
Total assets Total equity attributable to owners of the parent company

Changes of this year compared with last year

Changes of 2020 end over end

By order of the Board Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

18 March 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

* The Company is registered as a non-Hong Kong company under the Hong Kong

Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".